Many technology innovators are starting the year off strong with fresh injections of venture funding. London’s healthcare and artificial intelligence sectors received sizable capital raises to advance their solutions that streamline various tasks and processes. Learn which local innovators are fueling growth after a successful funding period in January.
Top London Tech Funding Rounds, January 2025
- Verdiva Bio Limited
- Neko Health
- Synthesia
- ElevenLabs
- Lindus Health
#4. £44 million, January 21
Using automation to help streamline clinical trials and get new medicines to market faster, Lindus Health secured a $55 million Series B raise led by Balderton Capital. The company has treated over 35,000 patients to date in clinical trials across Europe and the U.S. Its latest funding will support its commercial go-to-market team, expansion into new clinical trial types and integrations with third-party tools, like EHR systems.
#3. (tied) £144 million, January 30
ElevenLabs specializes in AI voice solutions. It recently secured $180 million in Series C funding to invest in advancing its AI audio technology, expanding its research and developing new products. A16z and ICONIQ Growth led the round that values ElevenLabs at $3.3 billion. ElevenLabs announced the opening of its London office, the center of its European headquarters operations, in 2024.
#3. (tied) £144 million, January 14
With a Series D capital raise equal to $180 million, AI avatar company Synthesia plans to invest in growing its team and fueling product advancement. The company is focusing on expanding its presence in the Asia Pacific with its new funding from lead investor NEA. Synthesia’s technology allows customers to build realistic-looking avatar-based videos from text documents. It also has various enterprise applications across sales, marketing and training.
#2. £208 million, January 23
Aiming to modernize preventative healthcare with its body scanning technology, Neko Health secured $160 million in Series B funding. The company has completed 10,000 scans to date across Stockholm and London and has a waitlist of more than 100,000. Lightspeed led the funding round that enables Neko Health to increase its capacity with new locations and regions.
#1. £330 million, January 9
Newly launched clinical-stage biopharmaceutical innovator Verdiva Bio works to develop therapies for cardiometabolic disorders including obesity. The company announced an oversubscribed Series A round totaling $411 million from lead investors Forbion and General Atlantic. Verdiva plans to invest in advancing its portfolio of oral and injectable treatments.
